載入中
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
收盤時
US$7.45
−US$0.19 · -2.49%
盤後
US$7.40
−US$0.05 · -0.67%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
日內區間
目前US$7.45
52週區間
目前US$7.45
盤中時間採用ET。市場資料可能有所延遲。
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
日內區間
目前US$7.45
52週區間
目前US$7.45
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.63億 USD | 2.63億 USD | 7850萬 USD | 1.31億 USD | 5360萬 USD |
| 銷貨成本 | 520萬 USD | — | — | — | — |
| 毛利 | 2.57億 USD | 2.63億 USD | 7850萬 USD | 1.31億 USD | 5360萬 USD |
| 研究與開發 | 2.83億 USD | 3.48億 USD | 3.8億 USD | 3.15億 USD | 1.8億 USD |
| 銷售、一般及管理費用 | 8940萬 USD | 1.65億 USD | 1億 USD | 7960萬 USD | 6160萬 USD |
| 營業費用 | 3.72億 USD | 5.14億 USD | 4.8億 USD | 3.95億 USD | 2.42億 USD |
| 利息收入 | 2200萬 USD | 5480萬 USD | 3880萬 USD | 1200萬 USD | 180萬 USD |
| 利息支出 | — | — | — | — | 10萬 USD |
| 折舊和攤銷 | 520萬 USD | 660萬 USD | 670萬 USD | 820萬 USD | 600萬 USD |
| 營業利益 | −1.15億 USD | −2.5億 USD | −4.02億 USD | −2.63億 USD | −1.88億 USD |
| 淨利 | −8080萬 USD | −1.99億 USD | −3.67億 USD | −2.83億 USD | −1.91億 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$14.17
上漲空間 90.20%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1767.03萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1200.58萬0.02%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF692.84萬0.01%954億 USD0.05%US$233.52-0.63%
Fidelity Enhanced Small Cap ETFFESM357.07萬0.05%64.1億 USD0.28%US$45.24-0.48%
iShares Biotechnology ETFIBB347.16萬0.03%108.2億 USD0.44%US$204.26-1.08%
State Street SPDR S&P Pharmaceuticals ETFXPH344.12萬0.75%4.69億 USD0.35%US$64.01-0.99%
Vanguard Russell 2000 ETFVTWO314.23萬0.02%180億 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA239.46萬0.01%218.24億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
